Gyre Therapeutics president Ma Songjiang sells shares price $42,960

SAN DIEGO—Ma Songjiang, President and Director of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a biotechnology firm with a market capitalization of roughly $958 million, lately offered a portion of firm inventory. In keeping with a submitting with the Securities and Change Fee, Ma disposed of a complete of 4,000 shares over two separate transactions on January 21 and 22, 2025. The inventory at the moment trades at $11.19, down about 26% over the previous yr.

The primary transaction concerned the sale of two,000 shares at a median value of $10.85 per share, whereas the second transaction noticed one other 2,000 shares offered at a median value of $10.63 per share. The entire worth of those gross sales amounted to roughly $42,960.

These transactions have been executed beneath a pre-established Rule 10b5-1 buying and selling plan, which Ma adopted on September 13, 2024. Following these gross sales, Ma retains oblique possession of two,903,138 shares, held by their partner.

In different latest information, Gyre Therapeutics has seen vital adjustments in its govt workforce. The biotechnology agency introduced the appointment of Ping Zhang, a seasoned govt with a powerful monetary background, because the lead unbiased director of its Board of Administrators. Zhang will even serve on the Nominating and Company Governance Committee. Moreover, Gyre Prescribed drugs, a subsidiary of Gyre Therapeutics, has appointed Songjiang Ma as its new Chairman, following Ying Luo’s choice to step down and focus on his function at GNI Group Ltd.

Zhang’s intensive expertise contains his present place as a Managing Companion at String Capital Administration and former roles at AEON Life Insurance coverage (NSE:LIFI) Firm and Japan Asia Funding Co. He has additionally held directorships at GNI and Asian Star Co.

By way of monetary efficiency, Gyre Therapeutics reported complete revenues of $105.03 million within the final twelve months, with a powerful gross revenue margin of 96.23%. The agency’s subsidiary, Gyre Prescribed drugs, is advancing its pipeline in China, together with ongoing medical trials for F351 and the commercialization of ETUARY® (Pirfenidone capsule), a number one remedy for idiopathic pulmonary fibrosis (IPF) in China with 2023 web gross sales of $112.1 million. These are a few of the latest developments at Gyre Therapeutics.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.